Architectural distortion on digital breast tomosynthesis mammograms in symptomatic breast clinics: what are the result outcomes?

Abstract

Abstract Objectives In April 2020, standard two-dimensional (2D) full-field digital mammograms were replaced with digital breast tomosynthesis (DBT) and synthesised 2D views for symptomatic breast clinics. This study aimed to evaluate the positive predictive value (PPV) for malignancy in DBT-detected Architectural distortion (AD). Methods All mammogram reports with the word “distortion” were assessed between April 2020 and October 2022. There were 458 mammograms with the word “distortion.” After excluding mammograms with no distortion (n = 128), post-surgical distortion (n = 173), distortion with mass (n = 33), and unchanged distortion (n = 14), there were 111 patients with pure distortion. Correlation with histopathology was obtained where possible. All patients were followed for a minimum of 2 years. Results Forty-two out of 111 patients (37.84%) with AD had a normal ultrasound (US) and were discharged. Fifty-five (49.5%) patients had sonographic correlation corresponding to the distortion, leading to US-guided biopsy. Thirteen (23.6%) had tomosynthesis-guided biopsy, and one had a skin biopsy. The PPV for malignancy was 42.34%. Malignancy diagnoses were higher with US-guided biopsies than tomosynthesis-guided biopsies, 78.1% and 30%, respectively. Conclusion With a total malignancy rate of 42.34%, DBT-detected AD has a high enough PPV for malignancy to justify selective tissue sampling if a sonographic correlate is present or with suspicious mammograms. The chances of malignancy are higher when a sonographic correlate corresponding to AD is present. Advances in knowledge AD on DBT/synthesized mammograms views in symptomatic breast clinic patients justifies selective sampling.